Cargando…
Refractory IgG Warm Autoimmune Hemolytic Anemia Treated with Eculizumab: A Novel Application of Anticomplement Therapy
Warm autoimmune hemolytic anemia (wAIHA) is the most common form of AIHA, with corticosteroids in first-line treatment resulting in a 60–80% response rate. Atypical wAIHA and IgG plus complement mediated disease have a higher treatment failure rate and higher recurrence rate. We report a case of sev...
Autores principales: | Ma, Kim, Caplan, Stephen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820603/ https://www.ncbi.nlm.nih.gov/pubmed/27092282 http://dx.doi.org/10.1155/2016/9181698 |
Ejemplares similares
-
Efficacy of eculizumab in refractory life‐threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia
por: Gauchy, Anne‐Cécile, et al.
Publicado: (2020) -
IgM-mediated Warm Autoimmune Hemolytic Anemia: An Autopsy Report
por: Ito, Takahiko, et al.
Publicado: (2018) -
Anticomplement therapy
por: Kulkarni, Prathit A, et al.
Publicado: (2008) -
IgG4-Related Disease Combined with Autoimmune Hemolytic Anemia and Steroid-Responsive Transient Hypercalcemia
por: Hasegawa, Sho, et al.
Publicado: (2015) -
Immunotherapy Treatments of Warm Autoimmune Hemolytic Anemia
por: Liu, Bainan, et al.
Publicado: (2013)